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Peripheral Blood Cells from Patients with Autoimmune
Addison’s Disease Poorly Respond to Interferons
In Vitro, Despite Elevated Serum Levels
of Interferon-Inducible Chemokines
Kine Edvardsen,1 Trine Bja˚nesøy,2 Alexander Hellesen,1,3 Lars Breivik,1 Marit Bakke,2
Eystein S. Husebye,1,3 and Eirik Bratland1
Autoimmune Addison’s disease (AAD) is a disorder caused by an immunological attack on the adrenal cor-
tex. The interferon (IFN)-inducible chemokine CXCL10 is elevated in serum of AAD patients, suggesting a
peripheral IFN signature. However, CXCL10 can also be induced in adrenocortical cells stimulated with IFNs,
cytokines, or microbial components. We therefore investigated whether peripheral blood mononuclear cells
(PBMCs) from AAD patients display an enhanced propensity to produce CXCL10 and the related chemokine
CXCL9, after stimulation with type I or II IFNs or the IFN inducer poly (I:C). Although serum levels of
CXCL10 and CXCL9 were significantly elevated in patients compared with controls, IFN stimulated patient
PBMC produced significantly less CXCL10/CXCL9 than control PBMC. Low CXCL10 production was not
significantly associated with medication, disease duration, or comorbidities, but the low production of poly
(I:C)-induced CXCL10 among patients was associated with an AAD risk allele in the phosphatase nonreceptor
type 22 (PTPN22) gene. PBMC levels of total STAT1 and -2, and IFN-induced phosphorylated STAT1 and -2,
were not significantly different between patients and controls. We conclude that PBMC from patients with AAD
are deficient in their response to IFNs, and that the adrenal cortex itself may be responsible for the increased
serum levels of CXCL10.
Introduction
Many patients with autoimmune diseases have signsof a continuous production of type I interferons (IFNs)
and display an increased expression of IFN-regulated genes
(Ronnblom 2011). In particular, patients with systemic
lupus erythematosus (SLE) have increased serum activity
of IFN-a and excessive signatures of interferon-stimulated
genes (ISGs) in peripheral blood leukocytes (Blanco and
others 2001; Bennett and others 2003). Clinical treatment of
infectious or malignant disorders with type I IFNs have also
been shown to induce autoantibodies and overt autoimmune
disease, hence, indicating a role for IFNs in breaking tol-
erance and promote on-going autoimmune reactions in man
(Karlsson-Parra and others 1990). In particular, endocrine
glands appear susceptible to IFN-induced autoimmune dis-
ease (Malik and others 2001; Michels and Eisenbarth 2010).
Prospective studies have shown that up to 15% of patients
receiving pegylated IFN-a therapy for chronic hepatitis C
virus (HCV) infections develop clinical thyroiditis, while
40% develop thyroid autoantibodies (Tomer 2010). More-
over, development of type 1 diabetes (T1D) during or shortly
after IFN-a therapy has been reported (Nakamura and others
2011). The involvement of the type I IFN pathway have
been suggested for both thyroiditis and T1D by increased
serum activity of type I IFNs (Mavragani and others 2013).
The principal type II IFN, IFN-g, is also heavily implicated
in these disorders as one of the major cytokines produced by
antigen-specific autoreactive T cells (Weetman 2004; Arif
and others 2014).
One archetypical ISG is the proinflammatory chemokine
CXCL10, which is strongly upregulated in response to both
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type I IFNs and IFN-g (Groom and Luster 2011). CXCR3,
the receptor for CXCL10, is highly expressed on activated
T cells implicating CXCL10 as an important mediator in the
recruitment of T cells to sites of inflammation (Qin and
others 1998). Elevated serum levels of this particular che-
mokine have been demonstrated in many autoimmune dis-
eases, including autoimmune thyroiditis and T1D (Antonelli
and others 2014) and in autoimmune Addison’s disease
(AAD) (Rotondi and others 2005; Kisand and others 2008;
Bellastella and others 2011; Bratland and others 2013;
Ekman and others 2014). AAD is a classic organ-specific
endocrine autoimmune disease, characterized by highly
targeted immune responses against specific antigens in the
adrenal cortex, in particular cytochrome P450 steroid 21-
hydroxylase (21OH) (Bratland and Husebye 2011). The
development of AAD is believed to be multifactorial, with
several predisposing genetic factors (Mitchell and Pearce
2012). Among these is the C1858T allele in the lymphoid
tyrosine phosphatase nonreceptor type 22 (PTPN22) gene,
a susceptibility allele for numerous autoimmune diseases
(Skinningsrud and others 2008; Roycroft and others 2009).
This single nucleotide polymorphism (SNP) causes an
amino acid shift from arginine to tryptophan at position
620, affecting the functional properties of PTPN22, in-
cluding its recently described role as a regulator of IFN
production in myeloid cells (Bottini and others 2004;
Wang and others 2013).
In addition to genetic and environmental factors, the cells
of the adrenal cortex probably also play an important role in
the pathogenesis of AAD. In this context it has been sug-
gested, and also experimentally demonstrated, that adreno-
cortical cells subjected to IFNs or cytokines are able to
attract 21OH-specific autoreactive T cells in a CXCL10-
specific manner (Kisand and others 2008; Bratland and
others 2013; Hellesen and others 2014). However, although
adrenocortical cells have been shown to produce large
amounts of CXCL10 upon IFN stimulation (Rotondi and
others 2005; Bratland and others 2013); it is still possible
that the elevated CXCL10 serum levels in AAD patients
are at least partially produced peripherally by leukocytes
(T cells or monocytes) due to an active IFN signature in the
peripheral blood. In this study we therefore characterized
the peripheral blood immune cell response to IFNs in AAD
patients, in particular with regard to CXCL10 production.
The data presented offer increased insight into the patho-
genesis of AAD, which is essential for future development
of novel therapeutic strategies complementing simple hor-
mone replacement therapy.
Materials and Methods
Patients and controls
Through the Norwegian registry and biobank for organ-
specific autoimmune diseases we have access to serum,
plasma, and peripheral blood mononuclear cells (PBMCs)
from patients with confirmed AAD. In total, 53 con-
secutively selected patients were recruited for this study.
Seventy-five age- and gender-matched healthy controls were
recruited from the local blood bank and from volunteers.
Samples from all patients and controls were not available for
all experiments (exact numbers are addressed in the figure
legends). All patients and controls signed informed consent
approved by the Health Region West Ethics Committee
(149/96-47.96) and all experiments were conducted in ac-
cordance with the Declaration of Helsinki.
PBMC isolation and stimulation
Heparinized blood samples from 19 AAD patients (see
Table 1 for patient details) and 21 controls were processed
essentially as described previously (Bratland and others
2013). In brief, plasma samples were isolated, aliquoted, and
kept frozen at - 20C, while PBMC were isolated using
Ficoll-Paque Plus (GE Healthcare). Upon isolation PBMC
Table 1. Information About the Patients Used in the Stimulation Experiments
Patient no. Sex
Disease
duration Age Comorbidity
Corticosteroid
rates (mg/day)
PTPN22 1858
genotype
1 F 19 46 — 25 C-C
2 F 31 55 — 30 C-C
3 M 15 41 T1D, V, Gr 37.5 C-C
4 F 0 26 T1D n/a C-C
5 M 15 55 — 31.25 C-C
6 F 14 58 — 37.5 C-C
7 F 12 49 — 37.5 C-C
8 F 9 61 HT 25 C-C
9 F 11 24 — 32 C-C
10 F 6 35 HT 37.5 C-C
11 F 1 52 Al 25 C-C
12 F 1 26 — n/a C-C
13 M 2 26 — 37.5 T-C
14 F 0 21 — 50 T-C
15 F 1 30 T1D, HT 25 T-C
16 M 1 60 — n/a T-C
17 F 0 40 HT 37.5 T-C
18 F 60 80 — 31.25 T-T
19 F 0 44 T1D, HT n/a T-T
Al, alopecia; Gr, graves; HT, Hashimoto’s thyroiditis; n/a, not available; PTPN22, phosphatase nonreceptor type 22; T1D, type 1
diabetes; V, vitiligo.
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were kept cryopreserved at -150C in 90% AB serum (Lonza)
and 10% dimethylsulphoxide (DMSO). PBMC stored at
- 150C were thawed, washed, and resuspended in serum-free
AIM V medium (Life-technologies). The cells were seeded at
1·106 cells in 500mL medium in 24-well culture plates, and
stimulated with various IFNs or polyinosinic:polycytidylic acid
(poly (I:C)) depending on the total number of cells available:
IFN-a (PBL Biomedical laboratories) at 104 U/mL, IFN-b
(RnD Systems) at 104 U/mL, IFN-g (Biolegend) at 1 mg/mL,
and poly (I:C), (Invivogen) at 10mg/mL. Optimal doses for
each stimulus were determined in preliminary experiments.
Nonstimulated cells grown in medium alone served as con-
trols. The concentrations of chemokines or IFNs induced by
medium alone were subtracted from the IFN- or poly (I:C)-
induced levels. The cells were grown for 24 h at 37C with
5% CO2 in a humidified incubator, upon which cells and su-
pernatants were harvested and stored at -80C for RNA iso-
lation and downstream assays, respectively.
ELISA for CXCL9 and CXCL10
Cell supernatants were tested for CXCL9 and CXCL10
content using DuoSet Sandwich ELISA kits from RnD
Systems. Plasma and serum levels of CXCL9 and CXCL10
were determined by sandwich ELISA kits validated for
plasma/serum analyses from RayBiotech, Inc.
RNA isolation from cultured PBMCs
and cDNA synthesis
Cultured PBMC were lysed in lysis buffer RLT (Qiagen)
and stored at - 80C. RNA was extracted using RNeasy
Mini Kit, Shredder and RNase Free Dnase Set (all from
Qiagen), and then purified and concentrated using RNeasy
MinElute Cleanup Kit (Qiagen) according to the manufac-
turer’s protocol. Purified RNA was stored at - 80C before
total RNA was reverse transcribed using iScript cDNA syn-
thesis Kit (Biorad), according to manufacturer’s protocol.
Quantitative real-time polymerase chain reaction
Primers were designed using Primer-BLAST (NCBI),
supplied by Life Technologies/Invitrogen and verified by
standard curve assessment (Table 2). Real-time polymerase
chain reaction (PCR) was performed in 10mL sample vol-
ume using Roche LightCycler 480 system containing 5mL
iQ Sybr Green Supermix (BioRad Laboratories Ltd), 0.5 mL
of each primer at 10 nM and 4mL of the previous reverse-
transcribed cDNA template. Two endogenous controls, porpho-
bilinogen deaminase (PBGD) and hypoxanthine phosphoribosyl
transferase 1 (HPRT1) were used for normalization. The proto-
col used is as follows: denaturation (95C for 5 min), amplifi-
cation repeated 40 times (95C for 10 s, 60C for 15 s, and 72C
for 15 s). A melt curve analysis (95C for 5 s, 65C for 1 min,
and then heated to 97C at 0.11C/s) was performed following
every run to ensure a single amplified product for every reaction.
All reactions were carried out in triplicate and repeated 2 or 3
times along with 2 negative controls (cDNA synthesized RNA
without reverse transcriptase and no template cDNA).
Bioassay for type I IFNs
The biological activity of type I IFNs in cell culture su-
pernatants were estimated using a commercial reporter cell-
line, HEK Blue IFN-a/b (Invivogen), which is stably
transfected with the necessary components of a fully func-
tional type I IFN pathway and a reporter gene expressing a
secreted embryonic alkaline phosphatase (SEAP) under
control of the ISG54 gene. HEK Blue IFN-a/b cells were
maintained in DMEM medium with Glutamax and high
glucose (4.5 g/L), supplemented with 10% (v/v) fetal bovine
serum, 50 U/mL streptomycin, 100 mg/mL normocin, 30 mg/
mL blasticidin, and 100mg/mL Zeocin. Cells were cultured
at 37C, 5% CO2, passaged at 70%–80% confluency and
maintained for no longer than 3 weeks to ensure genetic
stability. To estimate IFN activity, 20 mL of cell culture
supernatants were added to flat-bottomed 96-well culture
plates along with 5 · 104 HEK Blue IFN-a/b cells. Neu-
tralizing monoclonal antibodies against IFN-b (clone
MMHB-2, PBL Assay Science) were added to selected
wells (10 mg/mL) to estimate the relative amounts of each
type I IFN (-a or -b) produced. A standard curve was also
prepared using 2 fold dilutions of IFN-a over the range of
1.56–100 U/mL. After 20–24 h of cell culture 20 mL of the
induced HEK Blue IFN-a/b supernatant were mixed with
180mL QUANTI-Blue (Invivogen) SEAP substrate, a me-
dium that turns blue/purple in the presence of SEAP. After
2 h of incubation at 37C, the absorbance was measured at
650 nm, corresponding to the amount of SEAP produced in
response to IFNs.
Analysis of ISG expression
For the analysis of basic gene expression of selected IFN-
stimulated genes, peripheral blood was collected from 15
AAD patients and 15 healthy controls and CD4 + T cells
were isolated by the Dynabeads CD4 positive Isolation
Kit (Life Technologies/Invitrogen) according to the manu-
facturer’s protocol. Total RNA was immediately extracted
using RNeasy Mini Kits (Qiagen) following the manufac-
turer’s protocol and DNase I (Qiagen) was added to remove
remaining genomic DNA. Samples were stored at - 80C
before 1 mg of total RNA was reverse transcribed using
iScript cDNA synthesis Kit (Biorad) in total volume of 40mL,
according to manufacturer’s protocol. For the identification
of an IFN signature, we used a set of 5 genes previously
Table 2. Primers Used for Quantitative Real-Time
Polymerase Chain Reaction
Gene Primer sequence
USP18 FP: 5¢-CGTGGAACTCAGCAGCGG-3¢
RP: 5¢-TCAGGACAGCACGACTTCACTT-3¢
EIF2AK2 FP: 5¢-TCGCAAGACTATGGAAAGGAAG-3¢
RP: 5¢-CATCCCGTAGGTCTGTGAAAAA-3¢
CYP2E1 FP: 5¢-GACCTGTTCTTTGCGGGGA-3¢
RP: 5¢-CTTGATGGCAGGGATTCGG-3¢
CXCL10 FP: 5¢-GAACCTCCAGTCTCAGCACC-3¢
RP: 5¢-TGCAGGTACAGCGTACAGTT-3¢
IRF7 FP: 5¢-GAGCTGTGCTGGCGAGAAG-3¢
RP: 5¢-GGAGTCCAGCATGTGTGTGT-3¢
PBGD FP: 5¢-GAGCCAAGGACCAGGACATCT-3¢
RP: 5¢-AGTCAGGTACAGTTGCCCATCC-3¢
HPRT1 FP: 5¢-GCTTTCCTTGGTCAGGCAGTA-3¢
RP: 5¢-AACACTTCGTGGGGTCCTTT-3¢
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identified as IFN-regulated in peripheral blood after short-
term treatment with both type I and II IFNs: CXCL10,
CYP2E1, EIF2AK2, IRF7, and USP18. All selected IFN-
stimulated genes were previously shown to contain differ-
entially methylated regions in AAD patients compared with
healthy controls (Bjanesoy and others 2014). Quantitative
real-time PCR was performed as described above. Relative
quantification of the gene expression levels was calculated
for each individual by comparison with an average of all Ct
values measured in healthy blood donors and by normali-
zation against the reference genes PBGD and HPRT1. In-
dividual IFN scores were then calculated essentially as
described previously (Bilgic and others 2009): The 95th
percentile of expression levels was calculated for each gene,
and all measured individual expression levels were nor-
malized to the calculated 95th percentile value. Expression
values equal to or greater than the 95th percentile were
replaced with the 95th percentile so that the maximum value
for each gene was 1.0. The normalized expression levels for
the 5 analyzed genes were then summarized to yield the
final IFN score.
Analysis of STAT1 and STAT2 activation
To investigate if there were any differences in the STAT1/2
activation of stimulated cells in patients and controls, total
and phosphorylated STAT levels were measured using cell-
based ELISA immunoassays for human phospho-STAT 1
and 2 from R&D systems. The assay procedure from the
manufacturer was followed, using the protocol for non-
adherent cells. The cells were seeded at a concentration of
1.0 · 106 cells/mL and stimulated for 15 min with the same
concentration of stimuli (IFNs-a, -b, -g and poly (I:C)) used
in the PBMC stimulation experiments.
Genotyping of PTPN22 SNP
For all patients who donated cells to stimulation experi-
ments (n= 19), genomic DNA was extracted from peripheral
whole blood using QIAamp DNA Blood Mini kit (Qiagen).
Genotyping was conducted by means of PCR followed by a
restriction fragment length polymorphism assay (PCR-RFLP)
essentially as described previously (Bottini and others 2004).
A restriction site for the enzyme XcmI is present in the PCR
amplified fragment when an individual is carrying the 1858T
PTPN22 allele, but not when the person is homozygous for
the 1858C PTPN22 allele, meaning that the XcmI enzyme
cleaves the PCR product in the presence of the T nucleotide.
Cleavage of the PCR products was visualized with electro-
phoresis on a 3% agarose gel using GelRed. Genotypes for
all patients were also confirmed using conventional Sanger
DNA sequencing of ExoProStar (GE Healthcare) cleaned
PCR products.
Statistics
Statistical differences between patients and controls or be-
tween different patient groups were calculated using non-
parametric Mann–Whitney U-test. For correlation analyses, a
nonparametric Spearman test was used. All quantitative data
are expressed as the mean of duplicates or triplicates. For all
statistical operations, 2-tailed tests were used and P< 0.05
was considered significant. All tests were performed with
GraphPad Prism v5.02.
Results
Increased serum levels of CXCL9 and CXCL10
in AAD patients
Previous reports have shown that CXCL10 levels are el-
evated in AAD patients (Rotondi and others 2005; Bratland
and others 2013), so we initially determined the serum
levels of CXCL10 and CXCL9 in our patient cohort. We
observed a significant difference in the CXCL10 levels be-
tween patients and controls, where the mean was 546 pg/mL
in patients (range 3.4–3,153 pg/mL) and 228 pg/mL in con-
trols (range 0.0–1,757 pg/mL) (P < 0.05, Fig. 1a). A signif-
icant difference was also observed for the serum levels
of CXCL9 (AAD patients, mean 3,561 pg/mL, range 644–
7,500 pg/mL; controls, mean 2,384 pg/mL, range 259–
7,419 pg/mL) (P < 0.05, Fig. 1b). There were no significant
differences in serum levels of CXCL10 or CXCL9 between
patients with isolated AAD and patients with autoimmune
polyendocrine syndrome type 2 (APS-2), defined as AAD
plus additional autoimmune endocrinopathies (Supplemen-
tary Fig. S1; Supplementary Data are available online at
www.liebertpub.com/jir).
Deficient chemokine production in IFN-stimulated
PBMC from AAD patients
To investigate whether the increased serum levels of
CXCL10 in AAD patients reflect an increased IFN activity
in the patients’ peripheral blood, we stimulated PBMC
from patients and controls with types I and II IFNs and
FIG. 1. Plasma/serum levels of
CXCL10 and CXCL9. Sandwich
ELISA was used to assay for CXCL10
(a), and CXCL9 (b) contents in serum/
plasma samples from AAD patients
(n = 38) and healthy controls (n = 35
for CXCL10, n = 32 for CXCL9). The
results for each patient and control are
displayed as means of duplicates and
the bars display the mean for the
whole group. Nonparametric Mann–
Whitney U-test was used to test for
statistical differences between patients
and controls (*P< 0.05). AAD, auto-
immune Addison’s disease.
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determined the production of CXCL10. The levels of
CXCL10 were significantly lower in AAD patients than
controls, regardless of the source of IFN stimuli (P< 0.05
for IFN-a, -b and -g, Fig. 2a). We also assessed the pro-
duction of CXCL9, a chemokine preferentially induced by
IFN-g and only by a lesser degree by type I IFNs. As for
CXCL10, the induction of CXCL9 in PBMC was signifi-
cantly impaired in AAD patients compared with controls for
both type I and II stimulation (P < 0.001 for IFN-a and -b,
P < 0.05 for IFN-g, Fig. 2b). In a subset of patients and
controls, we also measured the levels of IFN-g and TNF-a
produced after stimulation with IFN-a and -b (Supplemen-
tary Fig. S2). Both cytokines were detectable at rather low
levels in both patients and controls. No significant differ-
ences were noted. Resting of the cells for 24 h before
stimulation did not appear to improve the CXCL10 pro-
duction from the patients’ PBMC relative to that of the
controls. Patient cells that had rested for 24 h before stimu-
lation with IFN-a showed both higher and lower production
of CXCL10 than cells stimulated directly (Supplementary
Fig. S3), while all the control cells tested had slightly in-
creased CXCL10 production in cells that were stimulated
after 24 h of resting. To assess whether the deficient re-
sponse to IFNs extended to other parts of the IFN pathways
we determined the relative mRNA levels of the 2 ISGs,
USP18, and IRF7 in response to IFN stimulation of PBMC
(Fig. 3). The mRNA levels of USP18 were significantly
lower in patients compared with controls for all 3 IFNs
(P< 0.05 for IFN-a, -b, and -g, Fig. 3a). For IRF7 no sig-
nificant difference in expression level was observed, al-
though the mean values were higher for controls for all IFNs
(Fig. 3b).
Deficient chemokine and IFN production in poly
(I:C)-stimulated PBMC from AAD patients
Because poly (I:C) is a TLR3 agonist mimicking viral
dsRNA and a well-known inducer of type I IFNs (and
therefore an indirect inducer of CXCL10), we determined
whether PBMC from the patients would respond differently
to poly (I:C) stimulation than healthy controls. The levels
of both CXCL10 and CXCL9 produced by PBMC were
FIG. 2. Levels of CXCL10 and CXCL9 production in PBMC stimulated with type I and II interferons (IFNs). Sandwich
ELISA was used to assay for CXCL10 (a) and CXCL9 (b) contents in supernatants from cells stimulated with type I (IFN-a
and IFN-b at 104 U/mL) and type II (IFN-g at 1 mg/mL) IFNs for 24 h. The results for each patient (IFN-a, n = 19; IFN-b,
n = 18; IFN-g, n = 14) and control (IFN-a, n = 21; IFN-b, n = 20; IFN-g, n = 20) are displayed as means of duplicates.
Nonparametric Mann–Whitney U-test was used to test for statistical differences between patients and controls for each IFN
(*P < 0.05, **P < 0.001). PBMC, peripheral blood mononuclear cell.
FIG. 3. Relative mRNA expression of USP18 and IRF7 in PBMC stimulated with type I and II IFNs. Real-time qPCR was
used to determine the relative mRNA expression of USP18 (a) and IRF7 (b) in PBMC stimulated with type I (IFN-a and
IFN-b at 104 U/mL) and type II (IFN-g at 1 mg/mL) IFNs for 24 h. The results for each patient (IFN-a, n = 19; IFN-b, n = 18;
IFN-g, n = 14) and control (IFN-a, n = 21; IFN-b, n= 20; IFN-g, n = 20) are displayed as means of triplicates. Nonparametric
Mann–Whitney U-test was used to test for statistical differences between patients and controls for each IFN (*P < 0.05). n.s.,
not significant; qPCR, quantitative real-time polymerase chain reaction.
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significantly reduced in patients (P < 0.001, Fig. 4). As for
IFN-a, patient cells that were stimulated with poly (I:C)
after 24 h of resting did not show consistently increased
CXCL10 production compared to cells stimulated directly at
the start of culture (data not shown). The mRNA levels of
both USP18 and IRF7 were also significantly lower in pa-
tients than controls after poly (I:C) stimulation (P< 0.05 for
both USP18 and IRF7, Fig. 5). The production of type I
IFNs (IFN-a and -b) in PBMC stimulated with poly (I:C)
were also investigated with a cellular reporter assay and
again found significantly lower in AAD patients compared
with healthy controls (P < 0.05, Fig. 6a). In a subset of
samples, using a modified version of the cellular reporter
assay, we also estimated the relative production of IFN-b
after poly (I:C) stimulation (Fig. 6b). Although the mean
production was higher among controls than the patients, the
difference was not statistically significant.
Correlations between chemokine production
and AAD patient characteristics
There were no significant differences in IFN- or poly
(I:C)-induced CXCL10 production between patients with
isolated AAD and APS-2 (Supplementary Fig. S4). For
CXCL9, PBMC from APS-2 patients produced significantly
higher levels after IFN-a and -b stimulation than PBMC
from patients with isolated AAD (Supplementary Fig. S5).
Furthermore, for the patients there were no significant cor-
relations between IFN- or poly (I:C)-induced CXCL10
or CXCL9 production and daily dose of cortisone acetate
(Supplementary Figs S6 and S7). With regard to disease
duration, no significant correlations were found for IFN- or
poly (I:C)-induced CXCL10 production, but there were
statistically significant inverse correlations between IFN-a
and b-induced CXCL9 and disease duration (Supplementary
Figs S8 and S9). When considering the age of the patients, a
statistically significant inverse correlation was found be-
tween IFN-g-induced CXCL10 and age (Supplementary Fig.
S10). No other significant correlations were found between
age and IFN- or poly (I:C)-induced CXCL10 or CXCL9
(Supplementary Fig. S11) production.
No evidence of an activated IFN signature
in the peripheral blood of AAD patients
To investigate the potentially dysregulated IFN pathway
in the peripheral blood of AAD patients, we compared the
expression profiles of 5 selected ISGs in 15 patients with 15
healthy controls. Although some patients clearly showed
signs of an activated IFN system, no significant differences
could be detected between patients and controls (Fig. 7).
Furthermore, no significant differences could be detected for
any of the single 5 selected ISGs (Supplementary Fig. S12).
IFN-stimulated levels of phosphorylated STAT1
and STAT2 are not different in PBMC from AAD
patients compared to controls
We subsequently investigated whether the poor response
to IFNs seen in the patients’ PBMC could be attributed to
deficient expression or phosphorylation of STAT1 and -2
upon IFN stimulation. In unstimulated PBMC no signifi-
cant differences in total STAT1 or -2 levels were evident
FIG. 4. Levels of CXCL10 and
CXCL9 production in PBMC stimu-
lated with poly (I:C). Sandwich ELI-
SA was used to assay for CXCL10 (a)
and CXCL9 (b) contents in superna-
tants from cells stimulated with poly
(I:C) (10 mg/mL) for 24 h. The results
for each patient (CXCL10, n = 15;
CXCL9, n = 13) and control (n = 15)
are displayed as means of duplicates.
Nonparametric Mann–Whitney U-test
was used to test for statistical differ-
ences between patients and controls
(**P< 0.001).
FIG. 5. Relative mRNA expression
of USP18 and IRF7 in PBMC stimu-
lated with poly (I:C). Real-time qPCR
was used to determine the relative
mRNA expression of USP18 (a) and
IRF7 (b) in PBMCs stimulated with
poly (I:C) (10mg/mL) for 24 h. The
results for each patient (n = 11) and
control (n= 15) are displayed as means
of triplicates. Nonparametric Mann–
Whitney U-test was used to test for
statistical differences between patients
and controls (*P< 0.05).
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between patients and controls (Fig. 8a, b). Furthermore,
although mean levels of phosphorylated STAT1 and -2 were
consistently lower in IFN- or poly (I:C)-stimulated PBMC
from patients compared with controls, no statistically dif-
ferences were detected (Fig. 8c, d).
Deficient responses to poly (I:C) associate
with PTPN22 1858 genotype
To find any characteristics among the AAD patients
that could help to explain their poor response to IFNs, we
looked in the literature and noted that a SNP of the PTPN22
gene (rs2476601) (which is associated with increased risk
for developing AAD) was also associated with impaired
IFN response after TLR stimulation in healthy individuals
(Wang and others 2013). Hence, all patients that donated
PBMCs to the stimulation experiments were genotyped for
the PTPN22 SNP at nucleotide 1858. Only 2 patients were
homozygous for the 1858T allele, while 5 were heterozy-
gous carriers. When stimulated with poly (I:C), there was a
significant difference in the production of CXCL10 between
carriers of the 1858T allele and the 1858C homozygotes
(P< 0.05, Fig. 9a). When the patients carrying the T allele
were removed from the original statistical calculations, the
difference in the poly (I:C)-induced production of CXCL10
was still significant, but the level of significance dropped
(P value with T carriers= 0.001, P value without T carriers=
0.0096). Although no other statistically significant associa-
tions were found, mean CXCL10 levels were lower in T
carriers also after IFN stimulation (as shown for IFN-a, Fig.
9b and IFN-b and -g, Supplementary Fig. S13). CXCL9
levels after IFN- or poly (I:C) stimulation on the other hand
seemed completely independent of PTPN22 genotype (Sup-
plementary Fig. S14).
Discussion
This study was performed to investigate whether an ab-
normal IFN signature is present in the peripheral blood of
patients with AAD, and if this can explain the elevated
serum levels of CXCL10 in AAD patients. The involvement
of IFNs, either type I or II or both, in the immunopathogen-
esis of AAD is strongly suggested by several observations in
both clinical and experimental settings: Individuals treated
with IFN-a for viral infections or cancer have developed
autoantibodies against 21OH, with or without concomitant
clinical adrenocortical insufficiency (Wesche and others
2001; Tran and others 2008; Krysiak and others 2011). In-
dividuals with subclinical and established AAD treated
with IFN-a have shown an exacerbation of the condition and
an increased need for glucocorticoid replacement (Knost
and others 1981; Oshimoto and others 1994). Furthermore,
we and others have shown experimentally that types I
and III IFNs are directly cytotoxic to adrenocortical cells
(van Koetsveld and others 2006; Hellesen and others
2014). Autoreactive 21OH-specific T cells producing large
amounts of IFN-g are also frequent in AAD patients
(Bratland and others 2009; Rottembourg and others 2010;
Dawoodji and others 2014), and tissue from deceased AAD
patients have revealed high expression of HLA class II on
FIG. 6. Levels of type I IFNs in PBMC stimulated with poly (I:C). Bioassay for type I IFNs was used to measure content
of total type I IFN (a) in supernatants from PBMC stimulated with poly (I:C) (10mg/mL) for 24 h. The results for each
patient (n = 15) and control (n= 16) are displayed as means of duplicates. IFN-b (b) content was estimated using a modified
bioassay with neutralizing anti-IFN-b antibodies in 7 patients and 5 controls [using the same supernatants as in (a)].
Nonparametric Mann–Whitney U-test was used to test for statistical differences between patients and controls (*P< 0.05).
FIG. 7. IFN signature genes are not upregulated in the
peripheral blood of AAD patients. Real-time qPCR was
used to determine the relative mRNA expression of 5 se-
lected ISGs in isolated CD4 + T cells. The IFN score for
each patient (n = 15) and control (n= 15) was calculated as
described in the Materials and Methods section. The bars
display the mean for the whole group. ISGs, interferon-
stimulated genes.
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adrenocortical cells, suggesting that these cells were indeed
exposed to IFN-g in vivo ( Jackson and others 1988).
Serum levels of CXCL10 and the related CXCL9 were
significantly elevated in the AAD patients recruited to this
study. There were no associations between serum chemo-
kine levels and disease duration or comorbidities. It has
previously been hypothesized that the elevated CXCL10
levels in serum are produced locally in the adrenal cortex
due to the presence of high levels of IFNs (Rotondi and
others 2005; Kisand and others 2008; Bratland and Husebye
2011; Bratland and others 2013). The source of these IFNs
could either be IFN-g secreting autoreactive T cells in the
process of killing adrenocortical cells, or an ongoing viral
infection inducing type I or III IFNs locally (by adreno-
cortical cells themselves and/or by resident tissue macro-
phages). However, CXCL10 in serum could also be
produced by peripheral blood cells (lymphocytes or mono-
cytes) due to an ongoing inflammatory process or an active
IFN signature in the AAD patients. Both excessive and
deficient CXCL10 production by PBMC upon IFN stimu-
lation has been described for other autoimmune disorders
with a defined peripheral IFN signature, such as SLE and
rheumatoid arthritis (Karonitsch and others 2009, 2012).
For all IFN subtypes tested, both CXCL10 and CXCL9
production by PBMCs were significantly lower in AAD
patients than controls. For some patients, no chemokine
production could be detected at all, despite the relatively
high doses of IFNs used for stimulation. Furthermore, there
were no obvious associations between chemokine levels and
disease duration or comorbidities of the patients, or between
the serum chemokine levels and the amount produced by
PBMCs after IFN stimulation. As expected, while CXCL10
was induced at equal degrees by all IFNs, CXCL9 was
predominantly induced by IFN-g (Groom and Luster 2011).
The small amount of CXCL9 induced by IFN-a/b stimu-
lation could in fact be a result of IFN-g, either alone or in
FIG. 8. Variations in STAT1/2 and
STAT1/2 phosphorylation in cells from
patients and controls stimulated with
IFNs and poly (I:C). Using a cell-based
ELISA PBMC from patients and con-
trols were stimulated for 15 min with
IFNs and poly (I:C), using the same
concentration as in previous experi-
ments. Total STAT1 (a) and total
STAT2 (b) are illustrated as mean
levels for the whole groups with stan-
dard error of the mean (SEM). Phos-
phorylated STAT1 (c) and STAT2 (d)
are shown as group means with SEM
for each stimulus in patients and con-
trols. Nonparametric Mann–Whitney
U-test was used to test for statistical
differences between the total STAT1
and -2 and phosphorylated STAT1 and
-2 in patients and controls (STAT1,
n= 8; STAT2, n= 7), but none were
found.
FIG. 9. Variations in poly (I:C) and IFN-a-induced CXCL10 production in patients with different PTPN22 1858 ge-
notypes. When the poly (I:C)-induced CXCL10 production was stratified by PTPN22 genotype a significant correlation
between carrying the T allele and low production of CXCL10 was found (a). Similar trends were found when IFN-induced
CXCL10 production was stratified according to PTPN22 genotype, although not reaching statistical significance, as shown
for IFN-a (b). Nonparametric Mann–Whitney U-test was used to test for statistical differences between the different
genotypes (*P < 0.05). PTPN22, phosphatase nonreceptor type 22.
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synergy with TNF-a, induced by the type I IFNs (Sareneva
and others 1998). IFN-g and TNF-a production was indeed
detectable in cell supernatants after type I IFN stimulations.
No significant differences were noted between patients and
controls for the type I IFN induced IFN-g and TNF-a, but as
the number of individuals tested was small this should be
interpreted with caution. There were significant negative
correlations between IFN-a and b-induced CXCL9 and
disease duration, which could indicate that the IFN-g pro-
duction in AAD patients with long lasting disease is defi-
cient and that this might partially explain the low CXCL9
production. The fact that both CXCL10 and CXCL9 pro-
duction was decreased in the patients indicated that both
type I and II IFN signaling pathways were deficient.
To further delineate the cause of the decreased chemokine
production the expression of 2 essential ISGs in the IFN-
stimulated PBMC, USP18, and IRF7 was investigated.
Ubiquitin-specific peptidase 18 (encoded by USP18) is a
classical ISG that provides a strong negative feedback signal
serving to downregulate the activation of the IFN-activated
Janus kinase-signal transducer and activator of transcription
( Jak-STAT) pathways (Malakhova and others 2006). Im-
portantly, the mRNA expression of USP18 was significantly
lower in AAD patients than healthy controls after IFN
stimulation, indicating that the poor response to IFNs is not
selective for chemokine production. Interferon regulatory
factor 7 (encoded by IRF7) is, as opposed to USP18, in-
duced in a positive regulatory feedback by type I IFNs
during antiviral responses (Marie and others 1998). Viral
infections or TLR (e.g. TLR3) engagement activates IRF7,
which initially participates in the transcriptional induction of
small amounts of type I IFNs. These IFNs then bind to IFN
receptors on adjacent cells, which in turn amplifies the ac-
tivation of IRF7 and consequently also the production of
IFNs (Ning and others 2011). However, the mRNA ex-
pression of IRF7 was not statistically different between
patients and controls after IFN stimulation, indicating that
the deficient chemokine response to direct stimulation with
IFNs in AAD patients is independent of IRF7.
To investigate chemokine production elicited by endo-
genous IFNs, we stimulated patient and control PBMCs with
the TLR3 agonist poly (I:C), a well-characterized inducer of
IFNs (Alexopoulou and others 2001). The chemokine pro-
duction was still significantly lower in AAD patients than
the controls. We also assessed the endogenous type I IFN
production itself, since the low production of CXCL10 after
poly (I:C) stimulation could either reflect the poor response
to direct stimulation with IFNs or point to an additional
defect in the endogenous production of type I IFNs. Again,
there was a statistically significant lower production of type
I IFNs in the AAD patients compared with the controls. We
also estimated the relative levels of IFN-b induced by poly
(I:C), but these levels were not significantly different be-
tween patients and controls. Furthermore, the expression
levels of USP18 were significantly lower among AAD pa-
tients than healthy controls, probably reflecting the decreased
levels of poly (I:C)-induced type I IFN in the patients. In
contrast to the findings with exogenous IFNs, the poly (I:C)-
induced gene expression levels of IRF7 were significantly
lower among AAD patients than controls. This could indicate
that the low chemokine production in AAD patients is a re-
flection of poor IFN production, and not primarily a conse-
quence of low sensitivity to exogenous IFNs. This is also
supported by the well-known fact that IFN-induced pro-
duction of ISGs in PBMCs includes a positive feedback loop
where additional endogenous types I and II IFNs are in-
duced and participates in enhancing the production of che-
mokines (Taniguchi and Takaoka 2002).
The poor production of IFN and IFN-induced chemokines
in AAD patients could be caused by IFN-induced refracto-
riness, known from chronic HCV infections where a pro-
longed endogenous stimulation with type I IFNs induces a
desensitization of cells to the IFN pathways, preventing
them from responding to exogenous IFNs (Makowska and
others 2011). IFN-induced refractoriness is also well de-
scribed in cell culture and animal models (Larner and others
1986; Sarasin-Filipowicz and others 2009). We therefore
looked at the gene expression of 5 classical ISGs in isolated
CD4 + T cells to investigate whether there were any signs of
prolonged activation of the endogenous IFN system in the
AAD patients. The 5 chosen ISGs were selected based on a
recent genome-wide DNA methylation study showing that
they all contained hypomethylated regions in AAD patients
compared with healthy controls (Bjanesoy and others 2014).
Although a few patients clearly had high expression levels
of single ISGs, no statistical difference in the calculated IFN
score could be detected between patients and controls. IFN-
induced refractoriness is therefore not a likely explanation
for the IFN-induced chemokine production in the AAD
patients. This is also supported by the fact that even USP18
were expressed at lower levels in patients than controls after
IFN stimulation, given that USP18 appears to be a key
mediator of IFN-induced refractoriness (Sarasin-Filipowicz
and others 2009; Francois-Newton and others 2011).
To narrow down our search for possible defects in the
molecular pathways of IFN signaling, we assessed the total
levels of STAT1 and STAT2 in unstimulated PBMC from
AAD patients and controls. We also compared phosphory-
lated STAT1/STAT2 levels after stimulation with IFNs-a,
-b, -g, or poly (I:C). No significant differences between
patients and controls were found for total STAT1/STAT2
levels, or for any IFN or poly (I:C)-stimulated STAT1/
STAT2 phosphorylation. These observations indicate that
the deficient responses to IFNs and poly (I:C) in AAD pa-
tients does not occur at type I or II IFN receptor/TLR3 levels
or upstream of STAT signaling. Instead, the defects in the
AAD patients may originate from signaling or transcriptional
events downstream of STAT1/STAT2 phosphorylation, or at
the production level of IFNs.
Another reason for the poor response to and production of
IFNs could be that patients with AAD are genetically prone
to this phenotype. A recent report showed that PTPN22,
traditionally regarded as a regulator of T-cell receptor sig-
naling, is also a regulator of the type I IFN system after TLR
stimulation (Wang and others 2013). Since the 1858T allele
of the PTPN22 gene is a risk variant for AAD, we geno-
typed all the AAD patients that were included in the PBMC
stimulation experiments and stratified their genotypes to the
their poly (I:C)-induced chemokine production. Strikingly,
the patients carrying the 1858T allele appeared to produce
less CXCL10 in response to poly (I:C) than patients ho-
mozygous for the 1858C allele. The statistically significant
difference in CXCL10 production after poly (I:C) stimula-
tion indicates that carriers of the 1858T allele are genetically
prone to produce less type I IFN (and hence CXCL10) upon
TLR3 stimulation than 1858C homozygotes, consistent with
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the recently described role for PTPN22 in IFN induction
(Wang and others 2013). However, the deficient chemokine
response to exogenous IFNs can hardly be explained by this
finding, as the IFN regulating role of PTPN22 is upstream of
IFN induction.
The decreased production of IFNs and chemokines in
AAD could in theory also be related to the cortisol supple-
mentation therapy given to the patients. High-dose intrave-
nous steroid treatment with methylprednisolone efficiently
downregulates the IFN signature in SLE leukocytes, although
more than 500-fold higher than the normal replacement
regimens that AAD patients adhere to are required (Bennett
and others 2003; Oksnes and others 2014). Still, it is a well-
known fact that glucocorticoids may interfere on the action
of IFN pathways in several ways, for example, by inhibiting
STAT1 phosphorylation or the heterotrimeric STAT1-
STAT2-IRF9 (ISGF3) transcription complex (Hu and others
2003; Bhattacharyya and others 2011). Thus, we performed
an experiment where in addition to stimulating the cells with
IFNs and poly (I:C) directly, we also rested the cells for 24 h
before stimulation. However, no improvement in CXCL10
production from patient PBMC relative to healthy controls
was observed. It should also be stressed that patients with
AAD have no endogenous glucocorticoid production, and in
general AAD patients on supplementation therapy do not
have increased serum cortisol levels (Methlie and others
2013). Still, there is a general concern that AAD patients
receive more glucocorticoids than the normal endogenous
production (Lovas and others 2009; Husebye and others
2014). Notably, however, there were no correlation between
the individual patients’ daily cortisol replacement doses and
chemokine responses to IFN stimulation in this study. This
could indicate that the cortisol treatment is not the expla-
nation for the generally decreased response.
There are some limitations to this study that needs to be
addressed. First, we generally used total PBMC for all
stimulation experiments without taking into consideration
the inter-individual variations in the distributions of the
PBMC subsets. In particular, the amount of monocytes in a
given individual could influence the results. However, we
are not aware of any studies reporting that AAD patients
have less monocytes among their PBMC than healthy in-
dividuals. Furthermore, patients were recruited to this study
in a consecutive manner, with no regard to disease duration.
Although there were no correlations between disease dura-
tion and IFN-stimulated chemokine production, disease
duration could be highly relevant when considering the
presence of an IFN signature in AAD patients. A recent
study of children genetically predisposed to develop T1D
revealed the presence of a transient IFN signature before the
onset of autoimmune disease (Ferreira and others 2014).
Also, it would have been interesting to add a more com-
prehensive list of ISGs for the studies of a possible IFN
signature and for the gene expression studies of IFN- and
poly (I:C)-stimulated PBMC. Unfortunately, this was not
possible for the current investigation due to a limited
number of cells and RNA from the patients.
To conclude, we have demonstrated that despite elevated
serum levels of the IFN-induced chemokines CXCL10 and
CXCL9, peripheral blood cells from patients with AAD are
deficient in the production of these chemokines and there is
no evidence for an IFN signature in the peripheral blood.
This deficiency may in part be related to a defect in the
endogenous production of type I IFNs in peripheral blood
cells that again could be linked to an AAD risk allele in the
PTPN22 gene. Taken together, these observations suggest
that the elevated CXCL10 levels in the serum of AAD
patients instead are locally produced in the adrenal cor-
tex, under the influence of an IFN-rich milieu. Future work
should focus on discovering the source and exact identity of
these IFNs.
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